Last Updated : September 28, 2023
In order to ensure a smooth and efficient process, it is important that sponsors pay careful attention to our documentation. As documentation posted to the website is subject to change, please access this content as it is needed instead of downloading and archiving it.
It is important to read the following documents in conjunction with the Pharmaceutical Reviews Update, which communicates updates to procedures and general program developments. To receive new issues of the Pharmaceutical Reviews Update, please subscribe to the Weekly Summary email.
The Procedures for Reimbursement Reviews details the process to be followed by all participants involved in a drug reimbursement review, and provides guidance to sponsors in the preparation of their applications.
The Procedures for Time-Limited Reimbursement Recommendations details the process for issuing time-limited recommendations. These are recommendations to publicly fund a drug or drug regimen for a certain period of time, based on the condition the drug sponsor will conduct ongoing clinical studies to address uncertainty in the evidence. Consult our Frequently Asked Questions for more information
The Non-Sponsored Reimbursement Review Procedures details the procedures to be followed by all participants involved in a nonsponsored reimbursement review. This review is requested in situations where the sponsor of a potentially eligible drug chooses not to submit through our sponsored drug reimbursement review process.
The Therapeutic Review Framework and Process lists the steps for the evidence-based review of publicly available sources regarding a therapeutic category of drugs or a class of drugs, to support drug listings and policy decisions, as well as to encourage the optimization of drug therapy.
The Procedures for Streamlined Drug Class Reviews describes the process for a Streamlined Drug Class Review, in which published clinical information is leveraged to provide decision-makers with timely evidence to support drug policy decisions and formulary management
The Procedures for Implementation Advice for Health Technologies describes the process for issuing implementation advice for various health technologies, including drugs, medical devices, and diagnostics. Our implementation advice is intended to address relevant implementation considerations or timely policy decisions. Implementation advice is most appropriate when there are limitations or gaps with available evidence and/or there is a need for additional consultation with subject matter experts to gather consensus regarding implementation issues (e.g., place of drug in therapy, implementation criteria where none exist, therapeutic alternatives during a drug shortage, alternate diagnostic agents).
There is a fee structure that applies to its drug reimbursement review processes, please consult the Fee Schedule for Pharmaceutical Reviews for complete details and Frequently Asked Questions about fee adjustments communicated in June 2023.
The following templates are to be used by sponsors in accordance with the requirements outlined in the Procedures for Reimbursement Reviews.
Pharmaceutical submission SharePoint access request form
Pre-submission meeting request form
Pre-submission meeting briefing paper template
Proposed place in therapy template
Tailored review application form
Request for deviation from pharmacoeconomic requirements form
Reimbursement status of comparators template
Regulatory and HTA status template
Patients accessing new drugs template
Letter for sending NOC to the template
Checklist for economic requirements
Implementation plan for a cell or gene therapy
Sponsor summary of clinical evidence template
Tailored review submission template
Clinician group input template
Industry input template (non-sponsored reimbursement reviews)
Sponsor comments on draft reports template
Stakeholder feedback on draft recommendation
Reconsideration request template
Identification of confidential information template
Procedural review request template
Stakeholder input on scope of a provisional funding algorithm
Stakeholder feedback on a draft provisional funding algorithm